Skip to main content

Main menu

  • Home
  • Content
    • Latest
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Alerts
    • Feedback
    • Folders
    • Help
  • Other Publications
    • Saudi Medical Journal

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Neurosciences Journal
  • Other Publications
    • Saudi Medical Journal
  • My alerts
  • Log in
Neurosciences Journal

Advanced Search

  • Home
  • Content
    • Latest
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Alerts
    • Feedback
    • Folders
    • Help
  • Follow psmmc on Twitter
  • Visit psmmc on Facebook
  • RSS
Review ArticleReview
Open Access

Treating epilepsy with options other than antiepileptic medications

Osama Y. Muthaffar
Neurosciences Journal August 2020, 25 (4) 253-261; DOI: https://doi.org/10.17712/nsj.2020.4.20200010
Osama Y. Muthaffar
Department of Pediatrics, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
SBPN, ABCN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • References
  • PDF
Loading

Article Figures & Data

Tables

    • View popup
    Table 1

    Treatable vitamin-responsive epilepsy.

    IndicationDose
    Pyridoxine (B6)-dependent epilepsyB6 15-30 mg/kg/d BID (up to 500 mg/day) or (50-100) mg IV with simultaneous EEG recording.
    Pyridoxal 5’-phosphate-dependent epilepsyPyridoxal 5’-phosphate (30–50 mg/kg TID)
    Folinic acid-responsive seizuresFolinic acid (3–5 mg/kg/dose)
    Biotinidase deficiencyBiotin (10 - 20 mg/day)
    Biotin-thiamine-responsive basal ganglia diseaseBiotin (5–10 mg/kg/dose) and thiamine (300–900 mg/day)
    Cerebral creatine deficiency syndromesGAMT deficiency:
    Oral creatine monohydrate (dosage of 400-800 mg/kg/day TID or more)
    Ornithine: 100 mg/kg/day
    AGAT deficiency:
    Oral creatine monohydrate (dosage of 400-800 mg/kg/day TID or more)
    CRTR deficiency:
    Creatine monohydrate 100-200 mg/kg/day TID
    Arginine 400 mg/kg/day TID
    Glycine 150 mg/kg/day TID
    GAMT - guanidinoacetate methyltransferase, AGAT - L-arginine:glycine amidinotransferase deficiency, CRTR - creatine transporter deficiency
    • View popup
    Table 2

    Mitochondrial cocktail supplements

    MedicationDose
    Riboflavin (B2)50–400 mg po OD in children and 50–400 mg po OD in adults
    Ubiquinone (coenzyme Q10)2–8 mg/kg po daily BID in children and 50–600 mg po OD in adults
    L-Creatine0.1 g/kg po OD; maximum 10 g/d in children and 5 g po OD or BID in adults
    L-Arginine150–300 mg/kg po BID to TID in children and adults
    L-Carnitine10–100 mg/kg daily po TID in children and 100–1000 mg per dose po BID to TID in adults
    Vitamin E1–2 IU/kg po daily in children and 100–200 IU po daily in adults
    Vitamin C5 mg/kg po daily in children and 50–200 mg po daily in adults
    Alpha-lipoic acid50–200 mg per day
    • View popup
    Table 3

    Review of Non-pharmacological options.

    ConditionsTreatmentsDose/notes
    Neuronal ceroid-lipofuscinoses type IICerliponase alfa3 years or older: 300 mg by intraventricular infusion once every other week
    Menkes diseaseCopper histidine or copper chlorideCooper histidine subcutaneous:
    Day 1: 50 µg/d
    Day 2: 100 µg/d
    Day 3 onward: 150 µg/d
    Copper chloride subcutaneous:
    Age <1 year: 250 µg 2x/day
    Age >1 year: 250 µg 1x/day
    Tuberous sclerosis complexEverolimus5 mg/m2 PO qd
    Epileptic encephalopathies like CSWS, LKS, Doose, Rassmusen.. etcIntravenous immunoglobulins1- or 5-day course of 2 g/kg intravenous
    SteroidsOral prednisolone (up to 5 mg/kg/d) over 2–4 weeks.
    Methylprednisolone IV: 20–30 mg/kg/d for 3–5 days
    Epileptic encephalopathies like Dravet syndrome and Lennox–Gastaut syndromeCannabidiol5-25 mg/kg/d oral QD
    Dravet syndromeFenfluramine10 to 20 mg daily
    Catamenial epilepsy, CSWS, LKSAcetazolamide10 to 15 mg/kg/d divided BID
    Focal lesion like DNET, FCD, gliomaFocal lesionectomy, lobectomy or laser ablation
    Mesial temporal sclerosisTemporal lobectomy
    Hemimegalencephaly or extensive unilateral cortical dysplasia, Rasmussen encephalitis, Sturge–Weber syndromeHemispherectomy
    Lennox Gastatut syndromeCorpus callosotomy
    LKSMultiple subpial transections
    CSWS - continuous spike and wave during sleep, LKS - Landau Kleffner syndrome, DNET - Dysembryoplastic neuroepithelial tumors, FCD - focal cortical dysplasia
PreviousNext
Back to top

In this issue

Neurosciences Journal: 25 (4)
Neurosciences Journal
Vol. 25, Issue 4
1 Aug 2020
  • Table of Contents
  • Cover (PDF)
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Neurosciences Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treating epilepsy with options other than antiepileptic medications
(Your Name) has sent you a message from Neurosciences Journal
(Your Name) thought you would like to see the Neurosciences Journal web site.
Citation Tools
Treating epilepsy with options other than antiepileptic medications
Osama Y. Muthaffar
Neurosciences Journal Aug 2020, 25 (4) 253-261; DOI: 10.17712/nsj.2020.4.20200010

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Treating epilepsy with options other than antiepileptic medications
Osama Y. Muthaffar
Neurosciences Journal Aug 2020, 25 (4) 253-261; DOI: 10.17712/nsj.2020.4.20200010
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Medication-overuse headache: clinical profile and management strategies
  • The role of exercise in Parkinson’s Disease
  • Review of electroencephalography signals approaches for mental stress assessment
Show more Review

Similar Articles

Navigate

  • home

More Information

  • Help

Additional journals

  • All Topics

Other Services

  • About

© 2025 Neurosciences Journal Neurosciences is copyright under the Berne Convention and the International Copyright Convention. All rights reserved. Neurosciences is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work. Electronic ISSN 1658-3183. Print ISSN 1319-6138.

Powered by HighWire